These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2184961)

  • 1. A preliminary report on the role of somatostatin analogue (SMS 201-995) in the management of children with tall stature.
    Hindmarsh PC; Pringle PJ; Di Silvio L; Brook CG
    Clin Endocrinol (Oxf); 1990 Jan; 32(1):83-91. PubMed ID: 2184961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a continuous infusion of a somatostatin analogue (octreotide) for two years on growth hormone secretion and height prediction in tall children.
    Hindmarsh PC; Pringle PJ; Stanhope R; Brook CG
    Clin Endocrinol (Oxf); 1995 May; 42(5):509-15. PubMed ID: 7621570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the long-acting somatostatin analogue SMS 201-995 on growth rate and reduction of predicted adult height in ten tall adolescents.
    Tauber MT; Tauber JP; Vigoni F; Harris AG; Rochicchioli P
    Acta Paediatr Scand; 1990 Feb; 79(2):176-81. PubMed ID: 2321479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children.
    Dickerman Z; Guyda H; Tannenbaum GS
    J Clin Endocrinol Metab; 1993 Sep; 77(3):652-7. PubMed ID: 8257527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of tall stature in boys with somatostatin analogue 201-995: effect on final height.
    Noordam C; van Daalen S; Otten BJ
    Eur J Endocrinol; 2006 Feb; 154(2):253-7. PubMed ID: 16452538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency.
    Tzanela M; Guyda H; Van Vliet G; Tannenbaum GS
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2487-94. PubMed ID: 8675565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity.
    Kirk JM; Trainer PJ; Majrowski WH; Murphy J; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):487-93. PubMed ID: 7955460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
    McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
    Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
    Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
    Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty.
    Lanes R; Gunczler P
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):197-202. PubMed ID: 9828907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF; Harris AG; Zhu XF; Deng JY
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of somatostatin analogue SMS 201-995 in non-insulin-dependent diabetes.
    Davies RR; Miller M; Turner SJ; Watson M; McGill A; Orskov H; Alberti KG; Johnston DG
    Clin Endocrinol (Oxf); 1986 Dec; 25(6):739-47. PubMed ID: 2888547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections.
    Sas T; de Muinck Keizer-Schrama S; Aanstoot HJ; Stijnen T; Drop S
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):741-7. PubMed ID: 10848879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion.
    Mehltretter G; Heinz S; Schopohl J; von Werder K; Müller OA
    Klin Wochenschr; 1991 Jan; 69(2):83-90. PubMed ID: 1902881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
    Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats.
    Flyvbjerg A; Jørgensen KD; Marshall SM; Orskov H
    Am J Physiol; 1991 Apr; 260(4 Pt 1):E568-74. PubMed ID: 2018120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinergic muscarinic blockade produces short-term suppression of growth hormone secretion in children with tall stature.
    Hindmarsh PC; Pringle PJ; Brook CG
    Clin Endocrinol (Oxf); 1988 Sep; 29(3):289-96. PubMed ID: 3251668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
    Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
    Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.